Norgine Successfully Completes the Acquisition of Theravia
Norgine has announced a significant milestone with its acquisition of Theravia, an international pharmaceutical company dedicated to developing therapies for patients suffering from rare and debilitating conditions. This successful transaction enhances Norgine's commitment to providing life-changing medications to patients facing high unmet medical needs.
Integration Process and Strategic Growth
Following the completion of the acquisition, Norgine is set to initiate a structured integration process. This will involve aligning the operations, systems, and teams from both companies to ensure a seamless transition.
Janneke van der Kamp, Chief Executive Officer of Norgine, expressed enthusiasm regarding the successful closure. She emphasizes that integrating Theravia will significantly bolster Norgine's expertise and broaden its portfolio in rare disease medications. This acquisition aligns with their growth strategy, particularly focused on increasing accessibility to critical products for patients in regions with high unmet medical needs.
Theravia's New Role within Norgine
As a direct outcome of this acquisition, Theravia is now a wholly owned subsidiary of Norgine. This transition is expected to create additional opportunities for innovation and collaboration, ultimately advancing treatments available for rare diseases.
About Norgine
Norgine stands out as a specialty pharmaceutical and consumer healthcare company, boasting annual revenues exceeding €550 million. With a history that spans over 120 years, Norgine has made strides in delivering transformative products to patients across key markets, including Western Europe and parts of the Asia-Pacific region.
The company adopts a holistic approach that integrates strong commercial capabilities with extensive medical, regulatory, and clinical expertise. With in-house manufacturing and robust supply networks, Norgine is well-equipped to bring high-quality medicines to over 25 million patients each year.
Characterized by agility and innovation, Norgine continually seeks to uphold its legacy of excellence and patient care, pushing the envelope in therapeutic innovation.
Frequently Asked Questions
What does Norgine's acquisition of Theravia mean for patients?
The acquisition enhances Norgine's capabilities in providing vital therapies for rare diseases, increasing patient access to needed medications.
Who is the CEO of Norgine?
Janneke van der Kamp is the Chief Executive Officer of Norgine, leading the company through this significant acquisition.
What is Norgine's revenue?
Norgine reports annual revenues of over €550 million, reflecting its strong position in the pharmaceutical industry.
In which regions does Norgine operate?
Norgine primarily operates in Western Europe, Australia, and New Zealand, focusing on delivering healthcare solutions to these markets.
How long has Norgine been in operation?
Norgine has a rich history, operating for more than 120 years and dedicating itself to improving patient health through innovative therapies.
